News Releases

News Releases

Oct 22, 2020 Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Tuesday,
Oct 05, 2020 Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced the closing of its initial public offering of
Sep 30, 2020 Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering
REDWOOD CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price of $19.00 per share, for gross proceeds of $190,000,000 million, before underwriting
May 18, 2020 Pulmonx Announces National Reimbursement in France for Zephyr Endobronchial Valves, a Revolutionary Treatment Option for Patients With Severe Emphysema/Copd
Redwood City, CA–May 18, 2020 — Pulmonx Corporation announced today that the French Health Ministry has granted national reimbursement for the Zephyr Endobronchial Valve, the first minimally-invasive treatment option for patients with severe emphysema, a form of Chronic Obstructive Pulmonary
May 12, 2020 A New Report Confirms Significant Benefits in Patient Reported Outcomes at One Year Following the Non-Surgical Zephyr Valve Procedure for COPD/Emphysema
Redwood City, CA–May 12, 2020—A new publication this month in the  Annals of the American Thoracic Society  confirms the effectiveness of the Zephyr Valve ®  in improving dyspnea (shortness of breath), ability to exercise, and quality of life for patients with COPD/emphysema.
May 05, 2020 Pulmonx Secures $66m in Financing to Support Commercial Acceleration of the Zephyr Valve System, a Minimally-Invasive Treatment for Severe Emphysema
REDWOOD CITY, Calif., May 5, 2020— Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group, a leading global life science investor.
Print Page
Email Alerts
Contact IR
RSS Feeds